Peptide inhibition of HIV-1: Current status and future potential

BioDrugs

Volumn 22, Issue 3, 2008, Pages 161-175

  Kaushik Basu, Neerja ^a   Basu, Amartya ^a   Harris, Dylan ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

HIV 1 entry inhibitors, general; HIV 1 infections, general; HIV entry inhibitors, general; HIV fusion inhibitors, general; HIV integrase inhibitors, general; HIV maturation inhibitors, general; HIV protease inhibitors, general

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CGP 53437; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; ELVITEGRAVIR; ENFUVIRTIDE; GENE PRODUCT; GLYCOPROTEIN GP 120; INDINAVIR; INTEGRASE; JE 2147; KYNOSTATIN 272; PEPTIDE NUCLEIC ACID; PROTEIN INHIBITOR; PROTEIN P51; PROTEIN P66; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBONUCLEASE H; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; T 1249; T 649; UNINDEXED DRUG; VIF PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CELL INTERACTION; CELL SURFACE; DIPLOIDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; RNA SPLICING; VIROGENESIS; VIRUS ASSEMBLY; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP120; HIV INTEGRASE INHIBITORS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; MEMBRANE FUSION; PEPTIDES; RECEPTORS, HIV; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 43749119570     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822030-00003     Document Type: Review

References (206)

1. 2007 AIDS epidemic update. Geneva: UNAIDS/WHO, 2007 [online]. Available from URL: http://www.who.int/mediacentre/news/releases/2007/pr61/en/index.html [Accessed 2008 Feb 5]
2. Declaration of Commitment on HIV/AIDS: "global crisis - global action". United Nations [online]. Available from URL: http://www.un.org/ga/ aids/coverage/FinalDeclarationHIVAIDS.html [Accessed 2008 Feb 26]
3. Advancing HIV prevention: new strategies for a changing epidemic. Morb Mortal Wkly Rep 2003; 52: 329-32
4. Golden MR, Brewer DD, Kurth A, et al. Importance of sex partner HIV status in HIV risk assessment among men who have sex with men. J Acquir Immune Defic Syndr 2004; 36 (2): 734-42
5. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242 (4882): 1168-71
6. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242 (4882): 1171-3
7. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. Top HIV Med 2006; 14 (3): 827-43
8. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57 (4): 619-27
9. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393 (6686): 648-59
10. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445 (7129): 732-7
11. Galanakis PA, Spyroulias GA, Rizos A, et al. Conformational properties of HIV-1 gp120/V3 immunogenic domains. Curr Med Chem 2005; 12 (13): 1551-68
12. Moore JP, Cao Y, Conley AJ, et al. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. J Acquir Immune Defic Syndr 1994; 7 (4): 332-9
13. Moore JP, Cao Y, Ho DD, et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994; 68 (8): 5142-55
14. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996; 70 (3): 1863-72
15. Sodroski J, Wyatt R, Olshevsky U, et al. Conformation of the HIV-1 gp120 envelope glycoprotein. Antibiotics Chemother 1996; 48: 184-7
16. Ferrer M, Harrison SC. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol 1999; 73 (7): 5795-802
17. Biorn AC, Cocklin S, Madani N, et al. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004; 43 (7): 1928-38
18. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide develop-ment. Antimicrob Agents Chemother 1997; 41 (7): 1521-30
19. McFadden K, Cocklin S, Gopi H, et al. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 2007; 67 (3): 617-29
20. Cocklin S, Gopi H, Querido B, et al. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol 2007; 81 (7): 3645-8
21. Boggiano C, Jiang S, Lu H, et al. Identification of a D-amino acid decapeptide HIV-1 entry inhibitor. Biochem Biophys Res Commun 2006; 347 (4): 909-15
22. Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160: 4018-25
23. Thapa M, Kuziel WA, Carr DJ. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81: 3704-13
24. Ajuebor MN, Wondimu Z, Hogaboam CM, et al. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol 2007; 170: 1975-88
25. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73
26. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77
27. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5
28. Pasi KJ, Sabin CA, Jenkins PV, et al. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol 2000; 111: 136-42
29. Taylor JM, Wang Y, Ahdieh L, et al. Causal pathways for CCR5 genotype and HIV progression. J Acquir Immune Defic Syndr 2000; 23: 160-71
30. Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194 (7): 926-30
31. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338 (1): 182-99
32. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78 (6): 2790-807
33. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16 (6): 339-54
34. Pastore C, Ramos A, Mosier DE. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004; 78 (14): 7565-74
35. Agrawal L, VanHorn-Ali Z, Berger EA, et al. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004; 103 (4): 1211-7
36. Imai M, Baranyi L, Okada N, et al. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. Biochem Biophys Res Commun 2007; 353 (4): 851-6
37. Zhou N, Luo Z, Luo J, et al. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry 2000; 39 (13): 3782-7
38. Luo Z, Fan X, Zhou N, et al. Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. Biochemistry 2000; 39 (44): 13545-50
39. Tamamura H, Araki T, Ueda S, et al. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 2005; 48 (9): 3280-9
40. Tamamura H, Mizumoto M, Hiramatsu K, et al. Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org Biomol Chem 2004; 2 (8): 1255-7
41. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89 (2): 263-73
42. Kliger Y, Gallo SA, Peisajovich SG, et al. Mode of action of an antiviral peptide from HIV-1: inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276 (2): 1391-7
43. Murakami T, Zhang TY, Koyanagi Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999; 73 (9): 7489-96
44. Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73 (2): 1719-23
45. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186 (8): 1389-93
46. Nakashima H, Masuda M, Murakami T, et al. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 1992; 36 (6): 1249-55
47. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91 (21): 9770-4
48. Shu W, Liu J, Ji H, et al. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 2000; 39 (7): 1634-42
49. Burton A. Enfuvirtide approved for defusing HIV. Lancet Infect Dis 2003; 3 (5): 260
50. Maggi P, Ladisa N, Cinori E, et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 53 (4): 678-81
51. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 2003; 8 (4): 279-87
52. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17 (5): 691-8
53. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002; 18 (10): 685-93
54. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46 (6): 1896-905
55. Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005; 7 (3): 139-47
56. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18 (8): 1137-46
57. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004; 292 (2): 251-65
58. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78: 4628-37
59. Reeves JD, Lee FH, Miamidian JL, et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79: 4991-9
60. Lalezari JP, Bellos NC, Sathasivam K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005; 191 (7): 1155-63
61. Eron JJ. Novel antiretroviral agents: HIV/AIDS annual update 2003 [online]. Available from URL: http://clinicaloptions.com/HIV [Accessed 2005 Feb 25]
62. Ray N, Harrison JE, Blackburn LA, et al. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 2007; 81 (7): 3240-50
63. Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 2004; 189 (6): 1075-83
64. Martin-Carbonero L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 2004; 6 (1): 61
65. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75 (18): 8605-14
66. Heil ML, Decker JM, Sfakianos JN, et al. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004; 78 (14): 7582-9
67. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568-75
68. Dervillez X, Huther A, Schuhmacher J, et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. Chem Med Chem 2006; 1: 330-9
69. Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129 (2): 263-75
70. Wang J, Smerdon SJ, Jager J, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci U S A 1994; 91 (15): 7242-6
71. Le Grice SF, Naas T, Wohlgensinger B, et al. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J 1991; 10 (12): 3905-11
72. Muller B, Restle T, Weiss S, et al. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J Biol Chem 1989; 264 (24): 13975-8
73. Baillon JG, Nashed NT, Kumar A, et al. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol 1991; 3 (10): 1015-9
74. Harris D, Lee R, Misra HS, et al. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 1998; 37 (17): 5903-8
75. Divita G, Restle T, Goody RS, et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994; 269 (18): 13080-3
76. Divita G, Rittinger K, Geourjon C, et al. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J Mol Biol 1995; 245 (5): 508-21
77. Morris MC, Robert-Hebmann V, Chaloin L, et al. A new potent HIV-1 reverse transcriptase inhibitor: a synthetic peptide derived from the interface subunit domains. J Biol Chem 1999; 274 (35): 24941-6
78. Depollier J, Hourdou ML, Aldrian-Herrada G, et al. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry 2005; 44 (6): 1909-18
79. Oz Gleenberg I, Herschhorn A, Goldgur Y, et al. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase. Arch Biochem Biophys 2007; 458 (2): 202-12
80. Gleenberg IO, Herschhorn A, Hizi A. Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). J Mol Biol 2007; 369 (5): 1230-43
81. Wang J, Wang HX, Ng TB. A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa. Peptides 2007 Mar; 28 (3): 560-5
82. Oroszlan S, Luftig RB. Retroviral proteinases. Curr Top Microbiol Immunol 1990; 157: 153-85
83. Pearl LH, Taylor WR. A structural model for the retroviral proteases. Nature 1987; 329 (6137): 351-4
84. Wlodawer A, Miller M, Jaskolski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245 (4918): 616-21
85. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27: 249-84
86. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72 (9): 7532-41
87. Marciniszyn Jr J, Hartsuck JA, Tang J. Mode of inhibition of acid proteases by pepstatin. J Biol Chem 1976; 251 (22): 7088-94
88. Marciniszyn Jr J, Hartsuck JA, Tang J. Pepstatin inhibition mechanism. Adv Exp Med Biol 1977; 95: 199-210
89. Agarwal NS, Rich DH. Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin. J Med Chem 1986; 29 (12): 2519-24
90. Kay J, Afting EG, Aoyagi T, et al. The effects of lactoyl-pepstatin and the pepsin inhibitor peptide on pig cathepsin D. Biochem J 1982; 203 (3): 795-7
91. Fitzgerald PM, McKeever BM, VanMiddlesworth JF, et al. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem 1990; 265 (24): 14209-19
92. Copeland TD, Wondrak EM, Tozser J, et al. Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor. Biochem Biophys Res Commun 1990; 169 (1): 310-4
93. Young SD, Payne LS, Thompson WJ, et al. HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1′ side chain on structure-activity. J Med Chem 1992; 35 (10): 1702-9
94. Thompson WJ, Fitzgerald PM, Holloway MK, et al. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1′ phenyl substituents: x-ray crystal structure assisted design. J Med Chem 1992; 35 (10): 1685-701
95. Weber IT, Wu J, Adomat J, et al. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate: interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur J Biochem 1997; 249 (2): 523-30
96. Miller M, Schneider J, Sathyanarayana BK, et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3Å resolution. Science 1989; 246 (4934): 1149-52
97. Grobelny D, Wondrak EM, Galardy RE, et al. Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. Biochem Biophys Res Commun 1990; 169 (3): 1111-6
98. Ghosh AK, Thompson WJ, Holloway MK, et al. Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. J Med Chem 1993; 36 (16): 2300-10
99. Qasmi D, de Rosny E, Rene L, et al. Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors. Bioorg Med Chem 1997; 5 (4): 707-14
100. Jaskolski M, Tomasselli AG, Sawyer TK, et al. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 1991; 30 (6): 1600-9
101. Jaskolski M, Miller M, Rao JK, et al. Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution. Biochemistry 1990; 29 (25): 5889-98
102. Murthy KH, Winborne EL, Minnich MD, et al. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. J Biol Chem 1992; 267 (32): 22770-8
103. Dukes CS, Matthews TJ, Lambert DM, et al. Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. AIDS Res Hum Retroviruses 1996; 12 (9): 777-82
104. Alteri E, Bold G, Cozens R, et al. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother 1993; 37 (10): 2087-92
105. Sakurai M, Higashida S, Sugano M, et al. Studies of HIV-1 protease inhibitors: II, incorporation of four types of hydroxyethylene dipeptide isosteres at the scissile site of substrate sequences. Chem Pharm Bull (Tokyo) 1993; 41 (8): 1378-86
106. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44 (8): 2093-9
107. Engstrom K, Henry R, Hollis LS, et al. An efficient, stereoselective synthesis of the hydroxyethylene dipeptide isostere core for the HIV protease inhibitor A-792611. J Org Chem 2006; 71 (14): 5369-72
108. Jungheim LN, Shepherd TA, Baxter AJ, et al. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. J Med Chem 1996; 39 (1): 96-108
109. Kiso Y, Matsumoto H, Mizumoto S, et al. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999; 51 (1): 59-68
110. Yoshimura K, Feldman R, Kodama E, et al. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylene cyclopropane nucleoside analogues. Antimicrob Agents Chemother 1999; 43 (10): 2479-83
111. Mimoto T, Hattori N, Takaku H, et al. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere. Chem Pharm Bull (Tokyo) 2000; 48 (9): 1310-26
112. Baldwin ET, Bhat TN, Gulnik S, et al. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure 1995; 3 (6): 581-90
113. Baldwin ET, Bhat TN, Gulnik S, et al. Structure of HIV-1 protease with KNI-272: a transition state mimetic inhibitor containing allophenylnorstatine. Adv Exp Med Biol 1995; 362: 445-9
114. Velazquez-Campoy A, Luque I, Todd MJ, et al. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci 2000; 9 (9): 1801-9
115. Sheha MM, Mahfouz NM, Hassan HY, et al. Synthesis of di- and tripeptide analogues containing alpha-ketoamide as a new core structure for inhibition of HIV-1 protease. Eur J Med Chem 2000; 35 (10): 887-94
116. Mimoto T, Terashima K, Nojima S, et al. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg Med Chem 2004; 12 (1): 281-93
117. Chellappan S, Kiran Kumar Reddy GS, Ali A, et al. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des 2007; 69 (5): 298-313
118. Chellappan S, Kairys V, Fernandes MX, et al. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins 2007; 68 (2): 561-7
119. Kotler M, Simm M, Zhao YS, et al. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol 1997; 71 (8): 5774-81
120. Potash MJ, Bentsman G, Muir T, et al. Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A 1998; 95 (23): 13865-8
121. Baraz L, Friedler A, Blumenzweig I, et al. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. FEBS Lett 1998; 441 (3): 419-26
122. Friedler A, Blumenzweig I, Baraz L, et al. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. J Mol Biol 1999; 287 (1): 93-101
123. Blumenzweig I, Baraz L, Friedler A, et al. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases. Biochem Biophys Res Commun 2002; 292 (4): 832-40
124. Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur J Biochem 2002; 269 (21): 5103-11
125. Camarasa MJ, Velazquez S, San-Felix A, et al. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes. Antiviral Res 2006; 71 (2-3): 260-7
126. Zhang ZY, Poorman RA, Maggiora LL, et al. Dissociative inhibition of dimeric enzymes: kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 1991; 266 (24): 15591-4
127. Babe LM, Rose J, Craik CS. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci 1992; (10): 1244-53
128. Schramm HJ, Nakashima H, Schramm W, et al. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem Biophys Res Commun 1991; 179 (2): 847-51
129. Schramm HJ, Billich A, Jaeger E, et al. The inhibition of HIV-1 protease by interface peptides. Biochem Biophys Res Commun 1993; 194 (2): 595-600
130. Schramm HJ, Boetzel J, Buttner J, et al. The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res 1996; 30 (2-3): 155-70
131. Franciskovich J, Houseman K, Mueller R, et al. A systematic evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides. Bioorg Med Chem Lett 1993; 3 (4): 765-8
132. Schramm HJ, Breipohl G, Hansen J, et al. Inhibition of HIV-1 protease by short peptides derived from the terminal segments of the protease. Biochem Biophys Res Commun 1992; 184 (2): 980-5
133. Schramm HJ, de Rosny E, Reboud-Ravaux M, et al. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol Chem 1999; 380 (5): 593-6
134. Dumond J, Boggetto N, Schramm HJ, et al. Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. Biochem Pharmacol 2003; 65 (7): 1097-102
135. Misumi S, Kudo A, Azuma R, et al. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. Biochem Biophys Res Commun 1997; 241 (2): 275-80
136. Misumi S, Morikawa Y, Tomonaga M, et al. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. J Biochem (Tokyo) 2004; 135 (3): 447-53
137. Bouras A, Boggetto N, Benatalah Z, et al. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J Med Chem 1999; 42 (6): 957-62
138. Merabet N, Dumond J, Collinet B, et al. New constrained "molecular tongs" designed to dissociate HIV-1 protease dimer. J Med Chem 2004; 47 (25): 6392-400
139. Bannwarth L, Kessler A, Pethe S, et al. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J Med Chem 2006; 49 (15): 4657-64
140. Broglia RA, Tiana G, Sutto L, et al. Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers. Protein Sci 2005; 14 (10): 2668-81
141. Dyda F, Hickman AB, Jenkins TM, et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266 (5193): 1981-6
142. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993; 12 (8): 3269-75
143. Engelman A, Liu Y, Chen H, et al. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J Virol 1997; 71 (5): 3507-14
144. Engelman A, Englund G, Orenstein JM, et al. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 1995; 69 (5): 2729-36
145. Hickman AB, Palmer I, Engelman A, et al. Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase. J Biol Chem 1994; 269 (46): 29279-87
146. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369 (9569): 1261-9
147. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43 (1): 1-5
148. Maroun RG, Gayet S, Benleulmi MS, et al. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 2001; 40 (46): 13840-8
149. de Soultrait VR, Caumont A, Parissi V, et al. A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase. J Mol Biol 2002; 318 (1): 45-58
150. Desjobert C, de Soultrait VR, Faure A, et al. Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase. Biochemistry 2004; 43 (41): 13097-105
151. Hehl EA, Joshi P, Kalpana GV, et al. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004; 78 (10): 5056-67
152. Wu X, Liu H, Xiao H, et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol 1999; 73 (3): 2126-35
153. Hutoran M, Britan E, Baraz L, et al. Abrogation of Vif function by peptide derived from the N-terminal region of the human immunodeficiency virus type 1 (HIV-1) protease. Virology 2004; 330 (1): 261-70
154. Oz Gleenberg I, Avidan O, Goldgur Y, et al. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase. J Biol Chem 2005; 280 (23): 21987-96
155. Zawahir Z, Neamati N. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. Bioorg Med Chem Lett 2006; 16 (19): 5199-202
156. Rosenbluh J, Hayouka Z, Loya S, et al. Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides. J Biol Chem 2007; 282 (21): 15743-53
157. von Schwedler UK, Stuchell M, Muller B, et al. The protein network of HIV budding. Cell 2003; 114 (6): 701-13
158. Garzon MT, Lidon-Moya MC, Barrera FN, et al. The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: a biophysical characterization. Protein Sci 2004; 13 (6): 1512-23
159. Hoglund S, Su J, Reneby SS, et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother 2002; 46 (11): 3597-605
160. Niedrig M, Gelderblom HR, Pauli G, et al. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol 1994; 75 (Pt 6): 1469-74
161. Sticht J, Humbert M, Findlow S, et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 2005; 12 (8): 671-7
162. Martin-Serrano J, Zang T, Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 2001; 7 (12): 1313-9
163. Strack B, Calistri A, Craig S, et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003; 114 (6): 689-99
164. Martin-Serrano J, Perez-Caballero D, Bieniasz PD. Context-dependent effects of L domains and ubiquitination on viral budding. J Virol 2004; 78 (11): 5554-63
165. Goila-Gaur R, Demirov DG, Orenstein JM, et al. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 over-expression. J Virol 2003; 77 (11): 6507-19
166. Demirov DG, Ono A, Orenstein JM, et al. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A 2002; 99 (2): 955-60
167. Bouamr F, Houck-Loomis BR, De Los Santos M, et al. The C-terminal portion of the Hrs protein interacts with Tsg101 and interferes with human immunodeficiency virus type 1 Gag particle production. J Virol 2007; 81 (6): 2909-22
168. Munshi UM, Kim J, Nagashima K, et al. An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem 2007; 282 (6): 3847-55
169. Usami Y, Popov S, Gottlinger HG. Potent rescue of human immunodeficiency virus type 1 late domain mutants by ALIX/AIP1 depends on its CHMP4 binding site. J Virol 2007; 81 (12): 6614-22
170. Lee S, Joshi A, Nagashima K, et al. Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol 2007; 14 (3): 194-9
171. Fisher RD, Chung HY, Zhai Q, et al. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 2007; 128 (5): 841-52
172. Demidov V, Frank-Kamenetskii MD, Egholm M, et al. Sequence selective double strand DNA cleavage by peptide nucleic acid (PNA) targeting using nuclease S1. Nucleic Acids Res 1993; 21 (9): 2103-7
173. Nielsen PE, Egholm M, Berg RH, et al. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254 (5037): 1497-500
174. Nielsen PE, Egholm M, Berg RH, et al. Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anticancer Drug Des 1993; 8 (1): 53-63
175. Kaushik N, Pandey VN. PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology 2002; 303 (2): 297-308
176. Mayhood T, Kaushik N, Pandey PK, et al. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 2000; 39 (38): 11532-9
177. Boutimah-Hamoudi F, Leforestier E, Senamaud-Beaufort C, et al. Cellular antisense activity of peptide nucleic acid (PNAs) targeted to HIV-1 polypurine tract (PPT) containing RNA. Nucleic Acids Res 2007; 35 (12): 3907-17
178. Tripathi S, Chaubey B, Ganguly S, et al. Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res 2005; 33 (13): 4345-56
179. Chaubey B, Tripathi S, Ganguly S, et al. A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology 2005; 331 (2): 418-28
180. Tisne C, Dardel F. Optimisation of a peptide library for screening specific RNA ligands by flow-injection NMR. Comb Chem High Throughput Screen 2002; 5 (7): 523-9
181. Tisne C, Guilliere F, Dardel F. NMR-based identification of peptides that specifically recognize the d-arm of tRNA. Biochimie 2005; 87 (9-10): 885-8
182. Chaloin L, Smagulova F, Hariton-Gazal E, et al. Potent inhibition of HIV-1 replication by backbone cyclic peptides bearing the Rev arginine rich motif. J Biomed Sci 2007; 14 (5): 565-84
183. Baraz L, Hutoran M, Blumenzweig I, et al. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. J Gen Virol 2002; 83 (Pt 9): 2225-30
184. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369: 787-97
185. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2003; 2 (7): 587-93
186. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70 (12): 8270-6
187. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206 (1): 527-34
188. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2 (7): 760-6
189. Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10 (9): 995-9
190. Khurana S, Kennedy M, King LR, et al. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific anti-bodies with human immunodeficiency virus-neutralizing activity. J Virol 2005; 79 (11): 6791-800
191. Chackerian B, Briglio L, Albert PS, et al. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004; 78: 4037-47
192. Dorfman T, Moore MJ, Guth AC, et al. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 2006; 281 (39): 28529-35
193. Zhang MY, Choudhry V, Sidorov IA, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317: 21-30
194. Okazaki T, Terabe M, Catanzaro AT, et al. Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice. J Virol 2006; 80 (21): 10645-51
195. Hamburger AE, Kim S, Welch BD, et al. Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 2005; 280 (13): 12567-72
196. He Y, Vassell R, Zaitseva M, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77 (3): 1666-71
197. Gahery-Segard H, Pialoux G, Figueiredo S, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol 2003; 77 (20): 11220-31
198. Kran AM, Sorensen B, Nyhus J, et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18 (14): 1875-83
199. Pinto LA, Berzofsky JA, Fowke KR, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999; 13 (15): 2003-12
200. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43 (4): 500-11
201. Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121-5
202. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533-9
203. Zhang XQ, Sorensen M, Fung M, et al. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006; 50: 2231-3
204. Moore JP, Sattentau QJ, Klasse PJ, et al. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992; 66: 4784-93
205. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75: 579-88
206. Yoshimura K, Shibata J, Kimura T, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 2005; 20: 2065-73